FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2559564103> ?p ?o ?g. }

• W2559564103 abstract "Abstract Autografting (AutoSCT) has been limited by high-relapse rates and conventional allografting (AlloSCT) by excessive TRM and toxicity in the treatment of Multiple Myeloma (MM). Reduced intensity conditioning for transplant (RICT), a less toxic procedure for AlloSCT that aims to exploit graft versus tumor effect, has been shown to achieve remissions in MM. High-dose therapy/AutoSCT followed shortly thereafter by RICT might improve outcomes in MM as compared to AutoSCT or conventional AlloSCT used alone. We compared two retrospective cohort of patients who underwent either tandem AutoSCT (HDT consisted of Melphalan 200 mg/m2) or AutoSCT followed closely by related RICT (patients with HLA-matched siblings). The two groups were matched for pre-transplant therapy, disease status at transplant, time from diagnosis to transplant. GVHD prophylaxis for RICT patients consisted of CyA/MTX. The major results are summarized in the Table. In the AutoSCT/RICT group the complete remission rate was higher (p=0.004) and the risk of disease progression after transplant was significantly reduced (p=0.005). All patients who reached CR responded after full chimerism and GVHD developed. This finding confirms the existence of a graft-versus-myeloma effect. Since the first clinical signs of response in remitters patients were noted between 70 and 120 days and maximum response between 160 and 200 days after RICT (after DLI in one patient), these responses should be considered immunological responses. These data suggest than an allograft following an AutoSCT significantly reduces the incidence of disease progression. Tandem ASCT (N=35) ASCT + RICT (n=20) Age, median 56 (range, 38–66) 51 (range, 34–63) Median prior cycles of Chemoth. 4 (range, 3–6) 4 (range, 3–6) Time from Dx to 1st AutoSCT (median mo.) 6 (range, 5–60) 9 (range, 7–42) Conditioning Regimen for AutoSCT Melphalan (200 mg/m2) Melphalan (200 mg/m2) Conditioning Regimen for RICT --- TBI/Fludarabine Complete Remission 14% 50% p=0.004) Disease-Free Survival at 3 yrs 11% 45% (p=0.005) Overall Survival at 3 yrs 66% 70% (p=NS) Median Follow-Up (mo.) 30 (range, 6–104) 38 (range, 5–59) Transplant-Related Mortality 0% 0% Median days from AutoSCT to RICT --- 80" @default.
• W2559564103 created "2016-12-08" @default.
• W2559564103 creator A5002261559 @default.
• W2559564103 creator A5004371298 @default.
• W2559564103 creator A5018952464 @default.
• W2559564103 creator A5020789491 @default.
• W2559564103 creator A5032732751 @default.
• W2559564103 creator A5035335560 @default.
• W2559564103 creator A5044869604 @default.
• W2559564103 creator A5058431464 @default.
• W2559564103 creator A5066780948 @default.
• W2559564103 creator A5081368450 @default.
• W2559564103 creator A5091769198 @default.
• W2559564103 date "2005-11-16" @default.
• W2559564103 modified "2023-09-27" @default.
• W2559564103 title "Autografting Followed Closely by Nonmyeloablative Allografting as Consolidation Immunotherapy Reduces Disease Progression Compared to Tandem Autografting in Multiple Myeloma." @default.
• W2559564103 doi "https://doi.org/10.1182/blood.v106.11.1126.1126" @default.
• W2559564103 hasPublicationYear "2005" @default.
• W2559564103 type Work @default.
• W2559564103 sameAs 2559564103 @default.
• W2559564103 citedByCount "0" @default.
• W2559564103 crossrefType "journal-article" @default.
• W2559564103 hasAuthorship W2559564103A5002261559 @default.
• W2559564103 hasAuthorship W2559564103A5004371298 @default.
• W2559564103 hasAuthorship W2559564103A5018952464 @default.
• W2559564103 hasAuthorship W2559564103A5020789491 @default.
• W2559564103 hasAuthorship W2559564103A5032732751 @default.
• W2559564103 hasAuthorship W2559564103A5035335560 @default.
• W2559564103 hasAuthorship W2559564103A5044869604 @default.
• W2559564103 hasAuthorship W2559564103A5058431464 @default.
• W2559564103 hasAuthorship W2559564103A5066780948 @default.
• W2559564103 hasAuthorship W2559564103A5081368450 @default.
• W2559564103 hasAuthorship W2559564103A5091769198 @default.
• W2559564103 hasConcept C126322002 @default.
• W2559564103 hasConcept C141071460 @default.
• W2559564103 hasConcept C2776364478 @default.
• W2559564103 hasConcept C2776694085 @default.
• W2559564103 hasConcept C2776755627 @default.
• W2559564103 hasConcept C2778684742 @default.
• W2559564103 hasConcept C2778822529 @default.
• W2559564103 hasConcept C2779263901 @default.
• W2559564103 hasConcept C2911091166 @default.
• W2559564103 hasConcept C71924100 @default.
• W2559564103 hasConceptScore W2559564103C126322002 @default.
• W2559564103 hasConceptScore W2559564103C141071460 @default.
• W2559564103 hasConceptScore W2559564103C2776364478 @default.
• W2559564103 hasConceptScore W2559564103C2776694085 @default.
• W2559564103 hasConceptScore W2559564103C2776755627 @default.
• W2559564103 hasConceptScore W2559564103C2778684742 @default.
• W2559564103 hasConceptScore W2559564103C2778822529 @default.
• W2559564103 hasConceptScore W2559564103C2779263901 @default.
• W2559564103 hasConceptScore W2559564103C2911091166 @default.
• W2559564103 hasConceptScore W2559564103C71924100 @default.
• W2559564103 hasLocation W25595641031 @default.
• W2559564103 hasOpenAccess W2559564103 @default.
• W2559564103 hasPrimaryLocation W25595641031 @default.
• W2559564103 hasRelatedWork W19571804 @default.
• W2559564103 hasRelatedWork W1981167605 @default.
• W2559564103 hasRelatedWork W2007459874 @default.
• W2559564103 hasRelatedWork W2142015222 @default.
• W2559564103 hasRelatedWork W2144075794 @default.
• W2559564103 hasRelatedWork W2353124159 @default.
• W2559564103 hasRelatedWork W2588907662 @default.
• W2559564103 hasRelatedWork W2590504931 @default.
• W2559564103 hasRelatedWork W2593658983 @default.
• W2559564103 hasRelatedWork W68159190 @default.
• W2559564103 isParatext "false" @default.
• W2559564103 isRetracted "false" @default.
• W2559564103 magId "2559564103" @default.
• W2559564103 workType "article" @default.